Mark Lackner - Dec 31, 2023 Form 3 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Scientific Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Mark Lackner
Stock symbol
ZNTL
Transactions as of
Dec 31, 2023
Transactions value $
$0
Form type
3
Date filed
1/3/2024, 08:19 PM
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ZNTL Common Stock 16.3K Dec 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZNTL Stock Option (Right to Buy) Dec 31, 2023 Common Stock 215K $25.60 Direct F2
holding ZNTL Stock Option (Right to Buy) Dec 31, 2023 Common Stock 23.7K $23.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted on February 1, 2023, each of which represent a contingent right to receive one share of common stock, and which vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of February 1, 2023, subject to the Reporting Person's continued serviced with the Issuer.
F2 The options were granted by the Issuer on November 1, 2022. The options vest over four years: 25% of the options vested on October 17, 2023 with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer.
F3 The options were granted by the Issuer on February 1, 2023. The options vest and become exercisable in 48 substantially equal monthly installments following the grant date.

Remarks:

Exhibit 24 - Power of Attorney